-
Taxonomy & unit
-
us-gaap: shares
-
Description
-
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
-
Summary
-
Inhibikase Therapeutics, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and change rate from Q2 2021 to Q3 2025.
- Inhibikase Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending September 30, 2025 was 90.1M shares, a 914% increase year-over-year.
- Inhibikase Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 23.7M shares, a 293% increase from 2023.
- Inhibikase Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 6.03M shares, a 42.7% increase from 2022.
- Inhibikase Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 4.22M shares, a 76.8% decline from 2021.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)